Business Description
Botanix Pharmaceuticals Ltd
ISIN : AU000000BOT2
Total Employee Number:
1Description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.05 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.56 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.62 | |||||
Beneish M-Score | 1.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -51.3 | |||||
3-Year EPS without NRI Growth Rate | -49.7 | |||||
3-Year FCF Growth Rate | -45.4 | |||||
3-Year Book Growth Rate | 72.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 183.78 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 6.52 | |||||
9-Day RSI | 22.95 | |||||
14-Day RSI | 33.04 | |||||
3-1 Month Momentum % | -43.75 | |||||
6-1 Month Momentum % | -71.61 | |||||
12-1 Month Momentum % | -92.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.56 | |||||
Quick Ratio | 1.56 | |||||
Cash Ratio | 1.14 | |||||
Days Inventory | 1040.84 | |||||
Days Sales Outstanding | 92.95 | |||||
Days Payable | 414.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.2 | |||||
Shareholder Yield % | -122.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.25 | |||||
Operating Margin % | -401.31 | |||||
Net Margin % | -404.7 | |||||
EBITDA Margin % | -377.91 | |||||
FCF Margin % | -355.47 | |||||
OCF Margin % | -354.58 | |||||
ROE % | -116.83 | |||||
ROA % | -81.35 | |||||
ROIC % | -179.85 | |||||
3-Year ROIIC % | -167.37 | |||||
ROC (Joel Greenblatt) % | -426.7 | |||||
ROCE % | -95.28 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.91 | |||||
PS Ratio | 1.91 | |||||
PB Ratio | 0.78 | |||||
Price-to-Tangible-Book | 1.14 | |||||
EV-to-EBIT | -0.65 | |||||
EV-to-Forward-EBIT | -4.55 | |||||
EV-to-EBITDA | -0.67 | |||||
EV-to-Forward-EBITDA | -4.55 | |||||
EV-to-Revenue | 2.53 | |||||
EV-to-Forward-Revenue | 0.8 | |||||
EV-to-FCF | -0.71 | |||||
| Price-to-Net-Current-Asset-Value | 1.14 | |||||
Earnings Yield (Greenblatt) % | -153.85 | |||||
FCF Yield % | -137.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BXPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Botanix Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.49 | ||
| EPS (TTM) ($) | -0.03 | ||
| Beta | 21.8374 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 9.93 | ||
| Volatility % | 96.86 | ||
| 14-Day RSI | 33.04 | ||
| 14-Day ATR ($) | 0.002873 | ||
| 20-Day SMA ($) | 0.023221 | ||
| 12-1 Month Momentum % | -92.24 | ||
| 52-Week Range ($) | 0.0114 - 0.29 | ||
| Shares Outstanding (Mil) | 2,720.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Botanix Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Botanix Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Botanix Pharmaceuticals Ltd Frequently Asked Questions
What is Botanix Pharmaceuticals Ltd(BXPHF)'s stock price today?
The current price of BXPHF is $0.01. The 52 week high of BXPHF is $0.29 and 52 week low is $0.01.
When is next earnings date of Botanix Pharmaceuticals Ltd(BXPHF)?
The next earnings date of Botanix Pharmaceuticals Ltd(BXPHF) is .
Does Botanix Pharmaceuticals Ltd(BXPHF) pay dividends? If so, how much?
Botanix Pharmaceuticals Ltd(BXPHF) does not pay dividend.
Guru Commentaries on OTCPK:BXPHF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Botanix | World First Human Clinical Study Shows Synthetic CBD Formula Eradicates Staphylococcus Aureus | 2021-02-02 |
Articles on Botanix Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers